ArticleClinical lymphoma, myeloma & leukemia2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
Article in Clinical lymphoma, myeloma & leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols.Blood advances · 2026Article
- Cytogenetic Profile of Chromosomal Aberrations in Leukemia Using the Fluorescence In Situ Hybridization (FISH) Method at a Tertiary Institution in Gauteng Province.Diagnostics (Basel, Switzerland) · 2025Article
- Clinical Characteristics and Treatment Outcomes of Acute Myeloid Leukemia in Adolescent and Young Adult versus Adult Patients: A Single-Center Experience in Qatar.Clinical hematology international · 2025Article
- Article
- Review
- Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC).Journal of cancer research and clinical oncology · 2022Article
- Improved Survival of Leukemic Mice Treated with Sodium Caseinate in Combination with Daunorubicin without Toxicity.Journal of oncology · 2021Article
- Outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia in adolescent patients.Bone marrow transplantation · 2020Article
- Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.Leukemia · 2019Article
- The novel three-way variant t(6;17;15)(p21;q21;q22) in acute promyelocytic leukemia with an FLT3-ITD mutation: A case report.Oncology letters · 2018Article
- Acute myelogenous leukemia in adolescents and young adults.Pediatric blood & cancer · 2018Review
- Treatment strategies for adolescent and young adult patients with acute myeloid leukemia.Blood · 2018Review
- Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.International journal of hematology · 2018Article
- Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.Journal of neuro-oncology · 2018Review
- Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature.BMC cancer · 2017Review
- Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer.Current hematologic malignancy reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundLittle is known about outcomes of acute myeloid leukemia (AML) in adolescents and young adults (AYA). The purpose of this study is to determine the characteristics and outcomes of AYA AML patients in comparison to older adult patients with AML. PATIENTS AND
methodsWe retrospectively analyzed all AML patients treated at our institution from 1965 to 2009 who were aged 16 to 29 years.
resultsAmong 3922 adult AML patients treated during this period, 432 (11%) were identified as AYA. Median age was 23 years (range, 16-29 years); 73 (17%) patients had core binding factor (CBF)-AML [inversion (16), translocation (8:21)], and 51 (12%) had acute promyelocytic leukemia. Complete remission (CR) rates were 93% for CBF AML, 78% for APL, 77% with diploid karyotype, and 68% for other AML. Univariate analysis demonstrated higher rates of CR, CR duration, and overall survival (OS) in the AYA group compared with older patients. On multivariate analysis, AYA age group was independently associated with improved CR rate and CR duration, with a trend for longer OS (P = .085).
conclusionOutcome of AYA AML patients is overall better than for older adults with AML. Despite improvements in treatments and outcomes over time, there is still need for improvement in AYA with AML particularly for those with AML other than CBF and APL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.